Does your patient have molecular residual disease? Signatera looks deeper in breast cancer
Personalized tumor-informed test for actionable intelligence in breast cancer
Stay updated on our latest data presentations
Line of Therapy Adjustment in a Patient with Advanced Triple- Negative Breast Cancer (TNBC) by Using Personalized ctDNA Test for Treatment Response Monitoring
Poster # 164
Presentation will be available after St Gallen International Breast Cancer conference
17th St. Gallen International Breast Cancer Conference 2021 | March 17-21, 2021
Georges Azzi, M.D.
Holy Cross Hospital Medical Group
Serial Circulating Tumor DNA (ctDNA) Analysis for Treatment Monitoring in an Inflammatory Triple-Negative Breast Cancer Patient
Presentation will be available after NCCN annual meeting
NCCN Annual Conference | March 18-20, 2021
Urmeel Patel, M.D.
Millennium Physicians
Signatera has been used in clinical trials for over 500 Breast Cancer patients and that number is growing. See our two recently announced Breast Cancer studies:
Dare Study
Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera
LEADER Study Part 2
Study to use Signatera to test effectiveness of Ribociclib in combination with endocrine therapy versus standard endocrine therapy